|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopres- sin antagonist, in healthy subjects 显示文摘 | Shoaf SE Mallikaarjun S Bricmont P | 2012 | Eur J Clin Pharmacol2012，68，2： | 1 |
| 2 | Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide A VP antagonist, and furosemide or hydrochlorothiazide 显示文摘 | SHOAF S BRAMER S BRICMONT P | 2007 | J Cardiovasc Pharmacol2007，50，2： | 1 |
| 3 | Pharma- cokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy caucasian and japanese male subjects 显示文摘 | SHOAF S E KIM S R BRICMONT P | 2012 | Eur J Clin Pharmacol2012，，68： | 1 |
| 4 | Efficacy of normal saline injection with andwithout heparin for maintaining intermittent intravenous site显示文摘 | Shoaf J Oliver S | 1992 | Appl-Nuts Res1992，5，1： | 1 |
| 5 | Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist,in healthy subjects显示文摘 | Shoaf SE Mallikaarjun S Bricmont P | 2012 | Eur J Clin Pharmacol2012，68，2： | 1 |
| 6 | Induction of CYP2E1 in liver,kldney, brain and intestine during chronic ethanol administration and withdrawal:evidence that CYP2E1 possesses a rapid phase half-life of 6 hours or less 显示文摘 | Roberts B J Shoaf S E Jeong K S | 1994 | Biochemical and Biophysical Research Communications1994，205，2： | 1 |
| 7 | Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist,in healthy subjects显示文摘 | Shoaf SE Mallikaarjun S Briemont P | 2012 | Eur J Clin Pharmacol2012，68，2： | 1 |
| 8 | Lack of effect of renal and hepatic impairment on the pharmacokinetics of aripiprazole显示文摘 | BRAMER S L SHOAF S SALAZAR D E | 2003 | Eur Neurosychopharmacol2003，13，4： | 1 |
| 9 | Efficacy of normal saline injection with and without heparin for maintaining intermittent intra- venous site显示文摘 | Shoaf J Oliver S | 1992 | Appl Nurs Res1992，5，1： | 1 |
| 10 | Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects 显示文摘 | SHOAF S WANG Z BRICMONT P | 2007 | JClinPharmacol2007，47，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员